Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells

Immunology Letters

Volumn 149, Issue 1-2, 2013, Pages 62-67

  Lanzilli, Giulia ^a   Traggiai, Elisabetta ^b   Braido, Fulvio ^c   Garelli, Valentina ^c   Folli, Chiara ^c   Chiappori, Alessandra ^c   Riccio, Anna Maria ^c   Bazurro, Gyada ^b   Agazzi, Alessia ^b   Magnani, Alessandra ^b   Canonica, Giorgio Walter ^c   Melioli, Giovanni ^b  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Immune stimulation; Lymphocytes; Polyvalent mechanical bacteria lysate; Therapy

Indexed keywords

BACTERIUM LYSATE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL EXTRACTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PLASMA CELLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84872736728     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.11.009     Document Type: Article

References (31)

1. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
2. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
3. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
4. Cabello H., Torres A., Celis R., El-Ebiary M., Puig de la Bellacasa J., XaubetA, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997, 10:1137-1144.
5. Papi A., Luppi F., Franco F., Fabbri L.M. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:245-251.
6. Cogo R., Ramponi A., Scivoletto G., Rippoli R. Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomic study. Acta Biomed 2003, 74:81-87.
7. Rossi G.A., Peri C., Raynal M.E., Defilippi A.C., Risso F.M., Schenone G., et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol Lett 2003, 86:85-91.
8. Rossi S., Tazza R. Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infections. A randomised, open, controlled clinical trial. Arzneimittelforschung 2004, 54:50-56.
9. Rosaschino F., Cattaneo L. Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered Polyvalent Mechanical Bacterial Lysates (PMBL). Acta Biomed 2004, 75:171-178.
10. Tricarico D., Varricchio A., D'Ambrosio S., Ascione E., Motta G. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial. Arzneimittelforschung 2004, 54:57-63.
11. Macchi A., Vecchia L.D. Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections. Arzneimittelforschung 2005, 55:276-281.
12. Banche G., Allizond V., Mandras N., Garzaro M., Cavallo G.P., Baldi C., et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. Int J Immunopathol Pharmacol 2007, 20:129-138.
13. Cazzola M., Noschese P., Di Perna F. Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. Ther Adv Respir Dis 2009, 3:59-63.
14. Braido F., Schenone G., Pallestrini E., Reggiardo G., Cangemi G., CanonicaGW, et al. The relationship between mucosal immunoresponse and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate. J Biol Regul Homeost Agents 2011, 25:477-485.
15. Braido F., Tarantini F., Ghiglione V., Melioli G., Canonica G.W. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis 2007, 2:335-345.
16. Cazzola M., Rogliani P., Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med 2008, 102:321-327.
17. Morandi B., Agazzi A., D'Agostino A., Antonini F., Costa G., Sabatini F., et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol Lett 2011, 138:86-91.
18. Lanzilli G., Falchetti R., Tricarico M., Ungheri D., Fuggetta M.P. In vitro effects of an immunostimulating bacterial lysate on human lymphocyte function. Int J Immunopathol Pharmacol 2005, 18:245-254.
19. Lanzilli G., Falchetti R., Cottarelli A., Macchi A., Ungheri D., Fuggetta M.P. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol 2006, 19:551-559.
20. Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten-van Mölken M., Beeh K.M., et al. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
21. Suryani S., Fulcher D.A., Santner-Nanan B., Nanan R., Wong M., Shaw P.J., et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010, 115:519-529.
22. Hoek K.L., Antony P., Lowe J., Shinners N., Sarmah B., Wente S.R., et al. Transitional B cell fate is associated with developmental stage-specific regulation of diacylglycerol and calcium signaling upon B cell receptor engagement. J Immunol 2006, 177:5405-5413.
23. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009, 206:139-151.
24. Quach T.D., Manjarrez-Orduno N., Adlowitz D.G., Silver L., Yang H., Wei C., et al. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J Immunol 2011, 186:4640-4648.
25. Klein U., Rajewsky K., Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689.
26. Berkowska M.A., Driessen G.J., Bikos V., Grosserichter-Wagener C., Stamatopoulos K., Cerutti A., et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011, 118:2150-2158.
27. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
28. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006, 203(7):1693-1700.
29. Franceschi C., Monti D., Sansoni P., et al. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995, 16:12-16.
30. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351.
31. Ferlazzo G., Morandi B., D'Agostino A., Meazza R., Melioli G., Moretta A., et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 2003, 33:306-313.